Case report: Toxic epidermal necrolysis induced by tislelizumab in a patient with esophageal squamous cell carcinoma
2024
Toxic Epidermal Necrolysis from Tislelizumab in Esophageal Cancer
Sample size: 1
publication
Evidence: low
Author Information
Author(s): Wu Shilong, Xu Chenyang, Liu Huafeng
Primary Institution: Ganzhou People’s Hospital, Ganzhou, China
Conclusion
Tislelizumab can cause severe toxic epidermal necrolysis in patients with esophageal cancer, and a simple treatment strategy is proposed.
Supporting Evidence
- Toxic epidermal necrolysis is a severe skin reaction that can occur with immune checkpoint inhibitors.
- The patient developed TEN after 18 days of treatment with tislelizumab and chemotherapy.
- Treatment involved corticosteroids and supportive care, leading to recovery.
- No standardized guidelines exist for treating TEN, highlighting the need for effective strategies.
Takeaway
A 70-year-old man got a serious skin reaction after cancer treatment with tislelizumab, but he got better with the right care.
Methodology
The patient was treated with intravenous methylprednisolone, immunoglobulin, and antibiotics, along with nutritional support and wound care.
Limitations
The limited number of cases prevents verification of the proposed treatment strategy's universality.
Participant Demographics
70-year-old male with locally advanced esophageal cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website